Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

A Randomized Phase 2 Study of Neratinib With or Without Fulvestrant for Patients With HER2-Positive, Estrogen Receptor-Positive Metastatic Breast Cancer

Clinical Breast Cancer(2025)10.1016/j.clbc.2025.05.009Source: DataRank Database

A Randomized Phase 2 Study of Neratinib With or Without Fulvestrant for Patients With HER2-Positive, Estrogen Receptor-Positive Metastatic Breast Cancer is a research paper published in Clinical Breast Cancer (2025). On theSindex it has a DataRank of 0.

N/A

0DataRank · unranked

Scored on demand from live citation data

0 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 0.00)OA: closedTopics (36)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (14)

Xiangying Chu ORCID,Tarah J. Ballinger ORCID,Nisha Unni ORCID,Sarah Sinclair ORCID,Robert Wesolowski ORCID

Live enrichment

PubMed:40484776 OpenAlex:https://openalex.org/W4410432681

National Institutes of Health

Grant: 5K08CA252639

Susan G Komen Breast Cancer Foundation

Grant: CCR21662707

Dana-Farber Cancer Institute

Italian Association for Cancer Research

Puma Biotechnology Inc

FWCI

0.00

Citation Percentile

0.1%

closedLicense: http://www.elsevier.com/open-access/userlicense/1.0/

publisherhttps://api.elsevier.com/content/article/PII:S1526820925001338?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1526820925001338?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.clbc.2025.05.009

repositoryhttps://pubmed.ncbi.nlm.nih.gov/40484776

Fields of Study

Advanced Breast Cancer TherapiesHER2/EGFR in Cancer ResearchBreast Cancer Treatment Studies

MeSH Terms

Circulating Tumor DNAFulvestrantProgression-Free SurvivalAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsFemaleHumansMiddle AgedQuinolinesReceptors, EstrogenBiomarkers, TumorReceptor, ErbB-2Erb-b2 Receptor Tyrosine Kinases

Keywords

NeratinibFulvestrantMedicineMetastatic breast cancerOncologyInternal medicineTrastuzumabBreast cancerClinical endpointPertuzumabAdverse effectEstrogen receptorTolerabilityClinical trialCancerSurvivalOutcomesCirculating Tumor Dna

Sustainable Development Goals

SDG 0: Good health and well-being

A Randomized Phase 2 Study of Neratinib With or Without Fulvestrant for Patients With HER2-Positive, Estrogen Receptor-Positive Metastatic Breast Cancer

FAIR Checklist

Authors (14)

Funding (5 grants)

Impact

Open Access

Topics